Abstracts tagged "Lupus"

Abstract Number: 2860 • 2013 ACR/ARHP Annual Meeting
Mir-26a, Mir-30b and HER2: New Players On Lupus Nephritis Pathogenesis
Patrícia Costa-Reis¹, Pierre Russo² and Kathleen E. Sullivan³, ¹Allergy and Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Pathology, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: microRNAS (miRNAs) are noncoding RNAs responsible for post-transcriptional gene silencing. These key regulatory molecules control the expression of multiple genes, so its dysregulation can…
Abstract Number: 1620 • 2013 ACR/ARHP Annual Meeting
Characterization Of a Jamaican Lupus Cohort: Proinflammatory Biomarkers and Disease Activity
Rohan Willis¹, Monica Smikle², Karel de Ceulaer³ and Silvia S. Pierangeli⁴, ¹Int Medicine/Rheumatology, University of Texas Medical Branch, Galveston, TX, ²Microbiology, University of the West Indies, Kgn 7, Jamaica, ³Microbiology, University of the West Indies, KIngston, Jamaica, ⁴Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX
Background/Purpose: Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are related systemic autoimmune diseases associated with proinflammatory prothrombotic biomarkers/cytokine (PPM) and antiphospholipid antibodies (aPL). Reports…
Abstract Number: 852 • 2013 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosous and Primary Sjogren’s Syndrome May Display Joint Erosions On MRI As Well As Healthy Control, But Cannot Be Considered As Erosive Disease Such As Rheumatoid Arthritis: : An MRI Observational Study Of 90 Subjects
Frédérique Gandjbakhch¹, Violaine Foltz², Jérôme Renoux³, Nahalie Cozic⁴, Nathalie Costedoat-Chalumeau⁵, Damien Sene⁶, Guillaume Mercy⁷, Zahir Amoura⁸, Jean-Charles Piette⁹, Nathalie Morel¹⁰, Pierre Bourgeois¹¹ and Bruno Fautrel¹², ¹Department of Rheumatology, APHP, Pitié Salpétrière Hospital, Universite Paris 6, Paris, France, ²APHP, Pitié Salpétrière Hospital, Universite Paris 6, Paris, France, ³Radiology, Pitie-Salpetriere Hospital, Paris, France, ⁴APHP, Pitie Salpetriere Hospital, department of statistics, Paris, France, ⁵Internal Medicine, Hopital Cochin, Paris, France, ⁶Internal Medicine, Hopital Lariboisière, Paris, France, ⁷APHP, Pitie-Salpétrière Hospital, paris, France, ⁸Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ⁹Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France, ¹⁰Internal Medicine, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ¹¹Rheumatology, APHP,Pitie-Salpetriere Hospital, Paris 6, Paris, France, ¹²Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France
Background/Purpose: Recent studies tend to demonstrate presence of MRI erosion in Systemic Lupus Erythematosous (SLE) and primary Sjogren’s syndrome (pSS). The objective of this study…
Abstract Number: 24 • 2013 ACR/ARHP Annual Meeting
Plasma Cells In Acute Systemic Lupus Erythematosus Flares Are Characterized By a Highly Diversified Repertoire Accentuated By Clonal Expansions Of VH4-34 Antibodies
Christopher Tipton¹, Christopher Fucile², Alex Rosenberg², Scott Jenks³, Jennifer Hom⁴, F. Eun-Hyung Lee⁴ and Inaki Sanz¹, ¹Medicine/Rheumatology, Emory University, Atlanta, GA, ²University of Rochester, Rochester, NY, ³Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁴Emory University, Atlanta, GA
Background/Purpose :Systemic Lupus Erythematosus (SLE) is an autoimmune disease in which faulty B cell tolerance promotes the generation of multiple autoantibodies of which anti-ds DNA,…
Abstract Number: 2798 • 2013 ACR/ARHP Annual Meeting
Bone Marrow In Systemic Lupus Erythematosus Patients Contain a Highly Elevated Proportion Of Somatically Mutated, Activated Naive Cells Comprised Of Substantial Clonal Expansions
Jennifer Hom¹, Christopher Tipton², Christopher Fucile³, Bridget Neary¹, Chungwen Wei⁴, F. Eun-Hyung Lee¹, Alex Rosenberg³ and Inaki Sanz², ¹Emory University, Atlanta, GA, ²Medicine/Rheumatology, Emory University, Atlanta, GA, ³University of Rochester, Rochester, NY, ⁴Rheumatology, Emory University, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease where autoreactive antibodies are produced as a result of abnormal B cell activation and broken self-tolerance. This…
Abstract Number: 1598 • 2013 ACR/ARHP Annual Meeting
Cognitive Dysfunction, a Non-Inflammatory Neuropsychiatric Syndrome In Systemic Lypus Erythematosus
Juanita Romero-Díaz¹, Alí Duarte-García², Sandra Juarez-Arellano³, Alba Cicero-Casarrubias¹, Hilda Fragoso-Loyo⁴, Luis Llorente⁵ and Jorge Sánchez-Guerrero⁶, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Medicine, Tufts Medical Center, Boston, MA, ³Department of Neurology, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ⁵Immunology and Rheumatology Department, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁶Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: Cognitive dysfunction (CD) affects 15 – 60% of SLE patients; nevertheless, its pathogenesis and predisposing factors are unknown. Objective: To identify factors associated with CD…
Abstract Number: 644 • 2013 ACR/ARHP Annual Meeting
Expansion Of CD4⁺CXCR3⁺ T Cells In Patients With Systemic Lupus Erythematosus (SLE) Correlates With Subclinical Atherosclerosis
Karim Sacre¹, Brigitte Escoubet², Nicolas Charles³, Antoine Dossier⁴, Marie-Paule Chauveheid⁵ and Thomas Papo¹, ¹Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, ²Cardiology, University Paris-7, INSERM U872, APHP, Bichat Hospital, Paris, France, ³INSERM U699, Paris, France, ⁴Internal Medicine, University Paris-7, APHP, Bichat Hospital, Paris, France, ⁵Internal Medicine,, University Paris-7, APHP, Bichat Hospital, Paris, France
Background/Purpose: The mechanisms for accelerated atherosclerosis in SLE remain unclear. As atherosclerosis is itself immune-mediated, features of SLE-associated immunity might explain accelerated cardiovascular disease beside traditional…
Abstract Number: 2 • 2013 ACR/ARHP Annual Meeting
Charaterization Of Micrornas Involved In The Regulation Of Atherotrhombosis In Antiphospholipid Syndrome and Systemic Lupus Erythematosus
Chary Lopez-Pedrera¹, Patricia Ruiz-Limon¹, Raul Teruel², Ángeles Aguirre Zamorano¹, Rosario M. Carretero-Prieto¹, Nuria Barbarroja¹, Antonio Rodriguez-Ariza³, Eduardo Collantes-Estevez⁴, Rocio gonzalez-Conejero², Constantino Martinez², Mª Jose Cuadrado⁵ and Carlos Perez-Sanchez¹, ¹Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ²Regional Centre for Blood Donation, University of Murcia, Murcia, Spain, ³Oncology Service and Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁴Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁵Lupus Research Unit, The Rayne Institute, London, United Kingdom
Background/Purpose: miRNAs are key players in pathophysiological processes, but no previous studies have investigated their asscociation with the cardiovascular and atherothrombotic risks observed in primary…
Abstract Number: 2700 • 2013 ACR/ARHP Annual Meeting
Abnormal Mitochondrial Electron Transport Chain Activity At Complex I Is Regulated By Nitric Oxide and N-Acetylcysteine In Lupus Lymphocytes
Edward Doherty¹ and Andras Perl², ¹Immunology, SUNY Upstate, Syracuse, NY, ²Dept of Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Systemic lupus erythematosus (SLE) peripheral blood lymphocytes (PBL) show mitochondrial dysfunction, characterized by elevated mitochondrial transmembrane potential (Δψm) and mass and low ATP, attributed…
Abstract Number: 1562 • 2013 ACR/ARHP Annual Meeting
Elevated Serum B-Cell Activating Factor (BAFF/BlyS) Characterises Disease Relapse Following Rituximab In Systemic Lupus Erythematosus
Lucy M. Carter¹, David A. Isenberg² and Michael R. Ehrenstein³, ¹University College London, London, United Kingdom, ²Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Rheumatology Research, University College London, London, United Kingdom
Background/Purpose: Numerous reports suggest that B cell depletion therapy (BCDT) using rituximab is effective in patients with systemic lupus erythematosus (SLE). However, two major trials…
Abstract Number: 613 • 2013 ACR/ARHP Annual Meeting
The Influence Of Cumulative Dose Of Corticosteroids On The Presence Of Carotid Atherosclerosis In Patients With Longstanding Systemic Lupus Erythematosus
Maria Rubino¹, Ellie Aghdassi², Sun Makosso-Kallyth³, Stacey Morrison⁴, Lihi Eder⁵ and Paul R. Fortin^6,7, ¹Internal Medicine, Université Laval, Quebéc, QC, Canada, ²University Health Network Research Institute and Department of Public Health, University of Toronto, Toronto, ON, Canada, ³Centre de Recherche CHU de Québec, Québec, QC, Canada, ⁴Div Rheumatology Rm MP-10-304, The Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Rheumatology, Division of Rheumatology, Université Laval, Québec, QC, Canada, ⁷Rheumatology, Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, Canada
Background/Purpose: The purpose of this study is to determine the relationship between cumulative corticosteroid dose (CCD) with presence of carotid plaques (CP), total plaque area…
Abstract Number: L18 • 2013 ACR/ARHP Annual Meeting
Long-Term Evaluation of Bone Mineral Density Change in Women Receiving Depot Leuprolide Acetate during Cyclophosphamide Therapy for Severe Lupus Nephritis
Nathan Meier¹ and Mary Anne Dooley², ¹Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Cohort studies demonstrate that 11-83% of female patients receiving cyclophosphamide (CYC) for treatment of severe manifestations of SLE develop premature ovarian failure (POF), dependent…
Abstract Number: 2675 • 2013 ACR/ARHP Annual Meeting
Phase 2 Trial On Triptorelin For Ovary Protection In Childhood-Onset Systemic Lupus Erythematosus
Rina Mina¹, Andreas Reiff², Clovis A. Silva³, Patricia Vega Fernandez⁴, Gloria C. Higgins⁵, Lisa F. Imundo⁶, Marisa S. Klein-Gitelman⁷, Calvin Williams⁸, Carol A. Wallace⁹, Nadia E. Aikawa¹⁰, Shannen L. Nelson¹¹, Jun Ying¹², Susan R. Rose¹³ and Hermine Brunner¹⁴, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ³Children's Institute, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁴Cincinnati Children's Hospital Medica Center, CINCINNATI, OH, ⁵Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ⁶Pediatric and Adult Rheumatology Columbia University Medical Center, New York, NY, ⁷Division of Rheumatology, Children's Memorial Hospital, Chicago, IL, ⁸Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁹University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ¹⁰Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ¹¹Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹²Medicine-Internal Medicine-General Medicine, University of Cincinnati, Cincinnati, OH, ¹³Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴PRCSG, Cincinnati, OH
Background/Purpose: Gonadotoxicity is a known side effect of cyclophosphamide (CYC) therapy in childhood-onset systemic lupus erythematosus (cSLE). Gonadotropin releasing hormone (GnRH) agonists, such as triptorelin,…
Abstract Number: 1579 • 2013 ACR/ARHP Annual Meeting
Novel Risk Factors For Thrombotic Thrombocytopenic Purpura In Systemic Lupus Erythematosus patients
Javier Merayo-Chalico¹, Diana Gómez-Martín², Roberta Demichelis-Gómez³, Sandra Rajme-Lopez², Luis Aparicio-Vera² and Jorge Alcocer-Varela², ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico, ³Haematology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico
Background/Purpose: Thrombotic thrombocytopenic purpura (TTP) is an uncommon disease characterized by thrombocytopenia and microangiopathic hemolytic anemia and, in some cases, fever, neurologic and/or renal abnormalities.…
Abstract Number: 582 • 2013 ACR/ARHP Annual Meeting
A Real-World Survey Of Clinical Practice Among Rheumatologists and Nephrologists In The United States Reveals Differences In Care Of Non-Nephritis Systemic Lupus Erythematosus and Lupus Nephritis As Compared With American College Of Rheumatology Treatment Guidelines
Neelufar Mozaffarian¹, Steve Lobosco² and Adam Roughley², ¹AbbVie, North Chicago, IL, ²Adelphi Real World Ltd., Macclesfield, United Kingdom
Background/Purpose: Current pharmacotherapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN) includes combinations of nonsteroidal anti–inflammatory drugs (NSAIDs), antimalarials (AMs), glucocorticoids (GCs), and cytotoxic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].